MA38287B1 - Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer - Google Patents

Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer

Info

Publication number
MA38287B1
MA38287B1 MA38287A MA38287A MA38287B1 MA 38287 B1 MA38287 B1 MA 38287B1 MA 38287 A MA38287 A MA 38287A MA 38287 A MA38287 A MA 38287A MA 38287 B1 MA38287 B1 MA 38287B1
Authority
MA
Morocco
Prior art keywords
treatment
cancer
prevention
new
aminopyrazine derivatives
Prior art date
Application number
MA38287A
Other languages
English (en)
Other versions
MA38287A1 (fr
Inventor
Bernard Christophe Barlaam
David Berry
Benedicte Delouvrie
Craig Steven Harris
Der Brempt Christine Marie Paul Lambert-Van
Gilles Ouvry
Gary Patrick Reid
Gary Peter Tomkinson
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd filed Critical Astrazeneca Ab
Publication of MA38287A1 publication Critical patent/MA38287A1/fr
Publication of MA38287B1 publication Critical patent/MA38287B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

)la présente invention concerne des composés de formule (i) (formule (i)) ou ses sels pharmaceutiquement acceptables, où r1 et r2 ont les mêmes significations que celles données dans la description; leurs procédés de préparation, des compositions pharmaceutiques les contenant et leur utilisation dans le traitement de troubles cellulaires prolifératifs.
MA38287A 2013-01-23 2014-01-22 Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer MA38287B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305078 2013-01-23
PCT/GB2014/050163 WO2014114928A1 (fr) 2013-01-23 2014-01-22 Composés chimiques

Publications (2)

Publication Number Publication Date
MA38287A1 MA38287A1 (fr) 2018-01-31
MA38287B1 true MA38287B1 (fr) 2018-08-31

Family

ID=47623992

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38287A MA38287B1 (fr) 2013-01-23 2014-01-22 Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer

Country Status (26)

Country Link
US (2) US9156831B2 (fr)
EP (1) EP2948447B1 (fr)
JP (1) JP6307096B2 (fr)
KR (1) KR102202516B1 (fr)
CN (1) CN104936953B (fr)
AP (1) AP2015008604A0 (fr)
AR (1) AR094553A1 (fr)
AU (1) AU2014208964B2 (fr)
BR (1) BR112015017331B1 (fr)
CA (1) CA2897279C (fr)
CL (1) CL2015002027A1 (fr)
CR (1) CR20150367A (fr)
DO (1) DOP2015000170A (fr)
ES (1) ES2608395T3 (fr)
IL (1) IL239890A0 (fr)
MA (1) MA38287B1 (fr)
MX (1) MX361136B (fr)
NI (1) NI201500096A (fr)
PE (1) PE20151979A1 (fr)
PH (1) PH12015501584A1 (fr)
RU (1) RU2644769C2 (fr)
SG (1) SG11201505631PA (fr)
TN (1) TN2015000313A1 (fr)
TW (1) TWI606047B (fr)
UY (1) UY35275A (fr)
WO (1) WO2014114928A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016146591A1 (fr) * 2015-03-16 2016-09-22 Astrazeneca Ab Traitement de combinaison
TW201726140A (zh) * 2015-09-17 2017-08-01 瑞典商阿斯特捷利康公司 治療癌症之新型生物標記及方法
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN107137405A (zh) * 2017-04-14 2017-09-08 黄德莲 一种治疗肾炎的药物组合物
CN110317190A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种三唑-羧酸酯类衍生物在医药领域的应用
CA3118493A1 (fr) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion de til utilisant des inhibiteurs de la voie akt
JP2022509019A (ja) 2018-11-05 2022-01-20 シンジェンタ パーティシペーションズ アーゲー 殺有害生物的に活性なアゾール－アミド化合物
EP3935053B1 (fr) 2019-03-08 2023-06-07 Syngenta Crop Protection AG Dérivés d'azole-amide à activité pesticide
US12552766B2 (en) 2019-03-20 2026-02-17 Syngenta Crop Protection Ag Pesticidally active azole amide compounds
BR112021018822A2 (pt) 2019-03-22 2021-11-23 Syngenta Crop Protection Ag Derivados de n-[1-(5-bromo-2-pirimidin-2-il-1,2,4-triazol-3-il)etil]-2-ciclopropil-6-(trifluorometil)piridina-4-carboxamida e compostos relacionados como inseticidas
MX2022013258A (es) 2020-04-24 2022-11-14 Astrazeneca Ab Formulaciones farmaceuticas.
CN114788829B (zh) * 2021-01-25 2023-06-20 广州嘉越医药科技有限公司 一种吡啶并[1,2-a]嘧啶酮类似物的应用

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7112373A (fr) 1970-09-25 1972-03-28
US4256887A (en) 1978-04-06 1981-03-17 Merck & Co., Inc. 1,2,4-Triazoles and a method for their preparation
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JP3028168B2 (ja) 1993-03-29 2000-04-04 住化ファインケム株式会社 ベンゼンスルホンアミド誘導体の製造方法
US5656416A (en) 1994-12-22 1997-08-12 Eastman Kodak Company Photographic processing composition and method using organic catalyst for peroxide bleaching agent
FI973205L (fi) 1995-02-02 1997-10-01 Smithkline Beecham Plc Indolijohdannaisia 5-HT-reseptoriantagonisteina
GB9517559D0 (en) 1995-08-26 1995-10-25 Smithkline Beecham Plc Novel compounds
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
JP2000515851A (ja) 1996-07-25 2000-11-28 メルク シヤープ エンド ドーム リミテツド ＧＡＢＡ▲下Ａα５▼レセプターサブタイプの逆アゴニストとしての置換のあるトリアゾロピリダジン誘導体
GB9711753D0 (en) 1997-06-06 1997-08-06 Merck Sharp & Dohme Therapeutic agents
KR100551853B1 (ko) 2000-07-19 2006-02-13 에프. 호프만-라 로슈 아게 피리미딘 유도체
WO2003045924A1 (fr) 2001-11-21 2003-06-05 Pharmacia & Upjohn Company Derives d'aryle-1,4-pyrazine substitues
US7012077B2 (en) 2001-12-20 2006-03-14 Hoffmann-La Roche Inc. Substituted cyclohexane derivatives
WO2003062224A1 (fr) 2002-01-17 2003-07-31 Eli Lilly And Company Composes azacycliques en tant que modulateurs de recepteurs d'acetylcholine
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
CA2484209C (fr) 2002-05-03 2013-06-11 Exelixis, Inc. Modulateurs de proteine kinase et procedes d'utilisation
GB0306097D0 (en) 2003-03-15 2003-04-23 Elam T Ltd Electroluminescent complexes
EP1606266A4 (fr) 2003-03-21 2008-06-25 Smithkline Beecham Corp Composes chimiques
DE10348044A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US20080207613A1 (en) 2004-01-12 2008-08-28 Cytopia Research Pty Ltd Selective Kinase Inhibitors
EP1742935B1 (fr) 2004-04-13 2010-02-24 Icagen, Inc. Pyrazines polycycliques tenant lieu de modulateurs du canal ionique du potassium
JP2006028056A (ja) 2004-07-14 2006-02-02 Agro Kanesho Co Ltd ピリミジン誘導体及びこれを含む有害生物防除剤
WO2006019833A1 (fr) 2004-07-26 2006-02-23 Eli Lilly And Company Derives d'oxazole en tant qu'agents de recepteur d'histamine h3, preparation et utilisations therapeutiques
EP1799667B1 (fr) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation comme agents therapeutiques
JP4958786B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
EP2289510A1 (fr) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques pour le traitement des maladies induites par des enzymes stearoyl-coa desaturase
WO2006065601A2 (fr) 2004-12-15 2006-06-22 Merck & Co., Inc. Inhibiteurs d'activite akt
WO2006084030A2 (fr) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Petites molecules inhibitrices du hsp90
AU2006258124B8 (en) 2005-06-10 2010-01-07 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
WO2007096764A2 (fr) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Dérivés d'hétéroaryles bicycliques en tant que modulateurs des récepteurs cannabinoïdes
WO2007111904A2 (fr) 2006-03-22 2007-10-04 Vertex Pharmaceuticals Incorporated Inhibiteurs de la c-met proteine kinase
TW200808800A (en) 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V
US20080039450A1 (en) 2006-06-22 2008-02-14 Jensen Annika J Compounds
JP5599610B2 (ja) 2006-06-30 2014-10-01 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０の阻害による神経変性疾患の処置
KR20090029274A (ko) 2006-07-21 2009-03-20 아이알엠 엘엘씨 Ｉｔｐｋｂ 억제제로서의 화합물 및 조성물
PT2057156T (pt) 2006-08-23 2017-05-04 Kudos Pharm Ltd Derivados de 2-metilmorfolina pirido-, pirazo- e pirimidopirimidina como inibidores de mtor
JP5206993B2 (ja) 2007-03-07 2013-06-12 日産化学工業株式会社 イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤
UY31293A1 (es) 2007-08-14 2009-03-31 Pirimidinas biciclicas fusionadas
WO2009024825A1 (fr) 2007-08-21 2009-02-26 Astrazeneca Ab Dérivés de 2-pyrazinylbenzimidazole en tant qu'inhibiteurs des récepteurs tyrosine kinase
BRPI0818533B8 (pt) 2007-10-11 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
JP2011500778A (ja) 2007-10-25 2011-01-06 アストラゼネカ・アクチエボラーグ ピリジン及びピラジン誘導体−０８３
JPWO2009072621A1 (ja) 2007-12-07 2011-04-28 日産化学工業株式会社 置換ジヒドロアゾール化合物及び有害生物防除剤
US20100298286A1 (en) 2007-12-20 2010-11-25 Novartis Ag Organic Compounds
JP2011507848A (ja) 2007-12-21 2011-03-10 ザ スクリプス リサーチ インスティチュート Ｒｈｏキナーゼインヒビターとしてのベンゾピランおよびアナログ
US20110105500A1 (en) * 2008-06-27 2011-05-05 S*Bio Pte Ltd. Pyrazine substituted purines
JP5564045B2 (ja) 2008-09-02 2014-07-30 ノバルティス アーゲー 二環式キナーゼ阻害剤
JP2010083883A (ja) 2008-09-08 2010-04-15 Nissan Chem Ind Ltd イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
JP2010063863A (ja) 2008-09-11 2010-03-25 Mugen:Kk ヘッドのフェース部背面に音響振動の異なるパイプまたは平板を複数設けた打点位置表示型ゴルフ練習用クラブとその製法
CN101676271B (zh) 2008-09-17 2011-12-14 山东轩竹医药科技有限公司 含有不饱和杂环胺的四环素衍生物
JP5702293B2 (ja) 2008-11-10 2015-04-15 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物
HRP20150341T1 (hr) * 2008-11-14 2015-05-08 Bayer Intellectual Property Gmbh Heterocikliäśki supstituirani spojevi arila kao inhibitori hif
BRPI0924084B1 (pt) * 2008-12-19 2021-12-21 Vertex Pharmaceuticals Incorporated Derivados de pirazina e composição farmacêutica que os compreende
WO2010075376A2 (fr) 2008-12-23 2010-07-01 Abbott Laboratories Composés antiviraux
WO2010086613A1 (fr) 2009-01-30 2010-08-05 Betagenon Ab Composés utiles en tant qu'inhibiteurs tel que ampk
KR20110114663A (ko) 2009-02-13 2011-10-19 바이엘 파마 악티엔게젤샤프트 융합된 피리미딘
EP2396331B1 (fr) * 2009-02-13 2013-10-16 Bayer Intellectual Property GmbH Pyrimidines condensées en tant qu'inhibiteurs d'akt
WO2010106457A2 (fr) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3,3.1]nonanes
GB0909441D0 (en) 2009-06-02 2009-07-15 Univ Sheffield Novel indole derivatives
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US8354403B2 (en) 2009-08-27 2013-01-15 Merck Sharp & Dohme Corp. Pyrrolidine derived beta 3 adrenergic receptor agonists
NZ598907A (en) 2009-10-20 2014-03-28 Cellzome Ltd Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
EP2338888A1 (fr) 2009-12-24 2011-06-29 Almirall, S.A. Dérivés d'imidazopyridine en tant qu'inhibiteurs JAK
WO2011089400A1 (fr) 2010-01-22 2011-07-28 Centro Nacional De Investigaciones Oncológicas (Cnio) Inhibiteurs de la pi3 kinase
ES2667049T3 (es) 2010-02-05 2018-05-09 Merck Patent Gmbh Derivados de heteroaril-[1,8]naftiridina
JP2011178673A (ja) 2010-02-26 2011-09-15 Nissan Chem Ind Ltd 非農園芸害虫の防除方法
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
EP2560488B1 (fr) 2010-04-23 2015-10-28 Cytokinetics, Inc. Aminopyridines et aminotriazines, leurs compositions et leurs procédés d'utilisation
AU2011253025A1 (en) 2010-05-12 2012-11-29 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CN102311396B (zh) 2010-07-05 2015-01-07 暨南大学 一种吡嗪类衍生物和其制备方法及在制药中的应用
ES2612503T3 (es) * 2010-09-14 2017-05-17 Exelixis, Inc. Compuestos 9H-purina como inhibidores de PI3K-delta y métodos para su preparación
US9181264B2 (en) * 2010-09-16 2015-11-10 Hutchison Medipharma Limited Fused heteroaryls and their uses
WO2012068589A2 (fr) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
CN102718745A (zh) * 2011-03-30 2012-10-10 中国科学院上海药物研究所 新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
WO2012162635A1 (fr) 2011-05-26 2012-11-29 Sunovion Pharmaceuticals Inc. Modulateurs des récepteurs 5 métabotropiques du glutamate et leurs procédés d'utilisation
WO2013049591A2 (fr) 2011-09-29 2013-04-04 Verseon Corporation Composés doublement inhibiteurs et procédés d'utilisation de ceux-ci
US20140044802A1 (en) 2012-04-05 2014-02-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof

Also Published As

Publication number Publication date
BR112015017331B1 (pt) 2022-01-11
MX361136B (es) 2018-11-28
IL239890A0 (en) 2015-08-31
US9657008B2 (en) 2017-05-23
TN2015000313A1 (en) 2017-01-03
KR20150109385A (ko) 2015-10-01
NI201500096A (es) 2016-02-16
CR20150367A (es) 2015-10-20
UY35275A (es) 2014-07-31
CN104936953A (zh) 2015-09-23
CN104936953B (zh) 2017-03-08
KR102202516B1 (ko) 2021-01-12
HK1214592A1 (en) 2016-07-29
WO2014114928A1 (fr) 2014-07-31
SG11201505631PA (en) 2015-08-28
MX2015009465A (es) 2015-09-28
CA2897279A1 (fr) 2014-07-31
MA38287A1 (fr) 2018-01-31
EP2948447B1 (fr) 2016-09-21
BR112015017331A2 (pt) 2017-07-11
JP6307096B2 (ja) 2018-04-04
TW201522329A (zh) 2015-06-16
AU2014208964A1 (en) 2015-08-06
AU2014208964B2 (en) 2016-09-01
ES2608395T3 (es) 2017-04-10
CL2015002027A1 (es) 2015-11-13
AP2015008604A0 (en) 2015-07-31
US20140206700A1 (en) 2014-07-24
CA2897279C (fr) 2020-12-29
TWI606047B (zh) 2017-11-21
US9156831B2 (en) 2015-10-13
PE20151979A1 (es) 2016-01-15
JP2016508484A (ja) 2016-03-22
BR112015017331A8 (pt) 2019-11-12
DOP2015000170A (es) 2015-08-16
RU2644769C2 (ru) 2018-02-14
RU2015132370A (ru) 2017-03-02
AR094553A1 (es) 2015-08-12
EP2948447A1 (fr) 2015-12-02
US20160137634A1 (en) 2016-05-19
PH12015501584A1 (en) 2015-10-05

Similar Documents

Publication Publication Date Title
MA38287A1 (fr) Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
MA38138A1 (fr) Dérivés inédits de quinolone
MA45223A (fr) Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant
MA42230B1 (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
MA38099A1 (fr) Des nouveaux composes triazolopyrazines substitues inhibiteurs des brd4
MA45222A (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA38999A1 (fr) Nouveaux composés hétérocycliques
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA37712A2 (fr) Inhibiteurs macrocycliques de virus flaviviridae
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
EA201590748A1 (ru) Противовирусные соединения против rsv
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
EA202192433A1 (ru) Соединения, полезные в терапии вич
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
EA201590450A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201291356A1 (ru) Пиперидиноновые производные как ингибиторы mdm2 для лечения рака
EA201291300A1 (ru) Производные нафт-2-илуксусной кислоты для лечения спида
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
MA38315B1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
MA38260A1 (fr) Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3